Latest Breaking News On - Hiddo heerspink - Page 1 : comparemela.com

Novartis: presented results for kidney disease

Novartis has presented the results of a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A receptor antagonist, in patients with.

ALIGN Study: Atrasentan Shows Significant Benefit on Proteinuria in IgAN at 36 Weeks

Atrasentan significantly reduces proteinuria in patients with IgA nephropathy, showing a 36.1% reduction compared to placebo at 36 weeks.

Diabetes Drug Enhances Heart, Kidney Health Outcomes

ERA and SGLT2 Inhibitor Combo Cuts Albuminuria in Chronic Kidney Disease

But ZENITH-CKD trial had to pivot to only using low-dose zibotentan due to fluid retention

Zibotentan/Dapagliflozin Mix Cuts Albuminuria in ZENITH-CKD Trial